Adial refines Phase 3 plans for AD04 in Alcohol Use Disorder, focusing on genetic subgroups and leveraging Cytel's advanced trial design expertise.

TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response ...

Data-Driven, Adaptive Trial Design: Adial partnered with Cytel to apply advanced statistical analytics and simulation ...

Tebipenem's approval in 2026 under SPA could bring Spero $400M+ in milestones & royalties. Read more on why SPRO is a Buy, ...

Black patients tend to experience more aggressive instances of MS and face greater barriers to diagnosis and treatment.

Mezzion Pharma Co., Ltd. (Mezzion) announced a major milestone in their clinical development program, having secured approximately $20 million USD in strategic funding to support the ongoing global ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase ...

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced ...

Brainstorm tapped Minaris to manufacture NurOwn for its upcoming Phase 3b clinical trial testing the treatment for ALS.

Enlicitide decanoate is an investigational oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

Phase 2 data expected in 2H 2026 - - KPL-387 Phase 1 single ascending dose data support profile for monthly dosing - LONDON, ...